A substance that activates any of the Wnt signalling pathway, a group of signal transduction pathways made of proteins that pass signals from outside of a cell through cell surface receptors to the inside of the cell.
ChEBI ID: 131492
| Member | Definition | Class |
|---|---|---|
| 1-azakenpaullone | An organic heterotetracyclic compound that is 7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indole substituted at positions 6 and 9 by oxo and bromo groups respectively. | 1-azakenpaullone |
| azd2858 | A member of the class of pyrazines that is pyrazine substituted by (pyridin-3-yl)aminocarbonyl, amino, and 4-(4-methylpiperazine-1-sulfonyl)phenyl groups at positions 2, 3 and 6, respectively. It is a potent inhibitor of GSK3alpha and GSK3beta (IC50 values of 0.9 and 4.9 nM, respectively) and increases bone mass (via Wnt activation) in rats. | AZD2858 |
| chir 98014 | A member of the class of aminopyrimidines that is pyrimidine substituted by {2-[(6-amino-5-nitropyridin-2-yl)amino]ethyl}amino, 2,4-dichlorophenyl, and 1H-imidazol-1-yl groups at positions 2, 4 and 5, respectively. It is a potent ATP-competitive inhibitor of GSK3alpha and GSK3beta (IC50 values of 0.65 and 0.58 nM, respectively). | CHIR-98014 |
| ly2090314 | A member of the class of diazepinoindoles that is 1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indole substituted by piperidin-1-ylcarbonyl, 4-(imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl and fluoro groups at position 2, 7 and 9, respectively. It is a potent ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3alpha and GSK-3beta. The drug is in clinical development for the treatment of advanced/metastatic cancer. | LY-2090314 |
| sporidesmin | An organic heteropentacyclic compound that has formula C18H20ClN3O6S2, produced by the saprophyte fungus Pithomyces chartarum. It is a mycotoxin responsible for the hepatogenous photosensitisation disease facial eczema in ruminants. | sporidesmin A |
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 18 (26.47) | 18.7374 |
| 1990's | 8 (11.76) | 18.2507 |
| 2000's | 13 (19.12) | 29.6817 |
| 2010's | 16 (23.53) | 24.3611 |
| 2020's | 13 (19.12) | 2.80 |
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (1.27%) | 5.53% |
| Reviews | 4 (5.06%) | 6.00% |
| Case Studies | 2 (2.53%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 72 (91.14%) | 84.16% |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 7.6021 | 1 | 3 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 12.8059 | 1 | 2 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 0.8597 | 1 | 3 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 3.4067 | 3 | 3 |
| G | Vesicular stomatitis virus | Potency | 7.6021 | 1 | 3 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 7.6021 | 1 | 3 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 7.6021 | 1 | 6 |
| Interferon beta | Homo sapiens (human) | Potency | 13.6331 | 2 | 9 |
| PPM1D protein | Homo sapiens (human) | Potency | 16.6486 | 1 | 4 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial | Homo sapiens (human) | IC50 | 6.2000 | 1 | 1 |
| Angiopoietin-1 receptor | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit beta | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit delta | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Casein kinase I isoform epsilon | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | IC50 | 2.5000 | 4 | 4 |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | IC50 | 2.0727 | 1 | 3 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | IC50 | 2.8000 | 1 | 1 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | Ki | 0.5400 | 1 | 1 |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | IC50 | 1.8000 | 1 | 1 |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | IC50 | 2.9236 | 3 | 5 |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | IC50 | 2.9236 | 3 | 5 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | Ki | 0.5400 | 1 | 1 |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | Ki | 0.5400 | 1 | 1 |
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | IC50 | 2.0727 | 1 | 3 |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | IC50 | 2.0000 | 3 | 3 |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | IC50 | 2.0000 | 2 | 2 |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | IC50 | 2.0000 | 2 | 2 |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | IC50 | 0.0058 | 5 | 5 |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | IC50 | 0.0057 | 12 | 13 |
| Glycogen synthase kinase-3 beta | Mus musculus (house mouse) | IC50 | 0.0760 | 1 | 1 |
| Glycogen synthase kinase-3 beta | Rattus norvegicus (Norway rat) | IC50 | 1.5590 | 2 | 4 |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | Ki | 0.0049 | 1 | 1 |
| Insulin receptor | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| LIM domain kinase 1 | Homo sapiens (human) | IC50 | 10.0000 | 4 | 4 |
| LIM domain kinase 2 | Homo sapiens (human) | IC50 | 10.0000 | 4 | 4 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Mitogen-activated protein kinase 12 | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Mitogen-activated protein kinase 13 | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Protein kinase C beta type | Homo sapiens (human) | IC50 | 0.4200 | 1 | 1 |
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | IC50 | 12.5000 | 2 | 2 |
| Serine/threonine-protein kinase Chk1 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| TGF-beta receptor type-2 | Homo sapiens (human) | IC50 | 1.2000 | 1 | 1 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 | 11.0000 | 2 | 2 |